Certara launches AI-powered drug development platform

Certara Inc. (NASDAQ: CERT) launched Certara IQ, an artificial intelligence-powered quantitative systems pharmacology platform designed to accelerate drug research and development processes.

The platform combines AI technology with computational modeling to help pharmaceutical companies predict drug interactions with biological systems and disease processes. The system aims to determine optimal dosing, therapeutic windows, and suitable patient populations for treatments.

According to the company, quantitative systems pharmacology-based FDA submissions have nearly doubled every 1.4 years since 2013. This modeling approach examines how drugs interact with biological systems by combining computational modeling with experimental data.

"Certara IQ represents the next step in making biosimulation a foundational capability across the entire drug discovery and development value chain," said William F. Feehery, chief executive officer. "By uniting AI, systems modeling and scientific expertise at scale, we're enabling companies to make smarter portfolio decisions, reduce development risk, and accelerate the delivery of new therapies to patients."

The platform features a generative AI-supported interface for building models, a repository of pre-built quantitative systems pharmacology models, and a high-performance simulation engine. The company states the system runs simulations thousands of times faster than traditional tools.

Certara IQ includes a no-code interface for analysis to assess drug feasibility, identify data gaps, and optimize dosing properties. The platform addresses previous limitations in quantitative systems pharmacology adoption, including long simulation times and complex coding environments.

Certara provides biosimulation software and services to more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.

You May Also Be Interested In

• Apple suing OpenAI over alleged misappropriation of trade secrets
• Axon adds two independent directors to its board
• Ideal Power (IPWR) files $75M mixed shelf